<DOC>
	<DOC>NCT02711202</DOC>
	<brief_summary>The aim of the study is to evaluate the efficacy of new immunosuppressive protocol based on two applications of anti-CD52 MabCampath (Alemtuzumab) a single dose of anti-TNF-α Remicade (infliximab) monoclonal antibodies in the early posttransplant period followed by either monotherapy based on tacrolimus or sirolimus.</brief_summary>
	<brief_title>Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Inclusion criteria: First deceaseddonor kidney transplantation Age &gt;18 years Donor &lt;65 years Cytomegalovirus (CMV)/ EpsteinBarr virus (EBV) seropositivity panel reactive antibodies (PRA) &lt;10% Written consent Exclusion criteria: Retransplantation, combined transplantation Prior immunosuppression less than 6 months prior transplantation Induction therapy with antibodies Leukopenia &lt; 4000, thrombocytopenia &lt; 100 000, Haemoglobin &lt; 80 g/l History of antithymoglobulin (ATG) or anticluster of differentiation 3 (CD3) monoclonals or antiTNFα Tuberculosis history Antihepatitis C virus (HCV) positivity, HBsAg HIV positivity Malignancy history Allergy to study medication Fertile women without contraception Pregnancy, breastfeeding mothers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>